Ipsen's Decapeptyl helps offset primary care sales decline
This article was originally published in Scrip
Executive Summary
Strong sales of Ipsen's prostate cancer treatment, Decapeptyl (triptorelin), and a good performance from the group's speciality care segment in general, helped to offset a 10% decline in primary care product sales during the first quarter. The French firm reported an overall increase in drug sales of 6% to €258 million, with group revenues also up by 6%, to €266 million.